TransMedics Group Inc (OQ:TMDX)
Business Focus: Advanced Medical Equipment & Technology
Apr 16, 2024 04:05 pm ET
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Apr 08, 2024 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., April 8, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 4, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 9,722 shares of its common stock and an aggregate of 6,322 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of
Mar 01, 2024 09:52 pm ET
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued...
Feb 27, 2024 05:59 pm ET
TransMedics Group Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises TransMedics Group, Inc. (NASDAQ: TMDX) investors that the law firm has initiated an investigation on behalf of investors that lost money on their TransMedics stock. TransMedics investors are encouraged to contact the...
Feb 27, 2024 02:00 am ET
TRANSMEDICS ALERT: Bragar Eagel & Squire, P.C. is Investigating TransMedics Group, Inc. on Behalf of TransMedics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) on behalf of TransMedics stockholders. Our...
Feb 26, 2024 08:07 pm ET
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.
Feb 26, 2024 04:28 pm ET
SHAREHOLDER ALERT: TransMedics Group Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Block & Leviton is investigating TransMedics Group, Inc. (NASDAQ: TMDX) for potential securities law violations. Investors who have lost money in their TransMedics Group investment should contact the firm to learn more about how they might recover...
Feb 26, 2024 03:05 pm ET
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
ANDOVER, Mass., Feb. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023.
Feb 16, 2024 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Feb. 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 4,041 shares of its common stock and an aggregate of 2,627 restricted stock units to 9 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee
Feb 12, 2024 03:05 pm ET
TransMedics to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
ANDOVER, Mass., Feb. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2023 after market close on Monday, February 26, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Jan 29, 2024 03:50 pm ET
New Innovation-Themed Whitepaper to Debut at the February 1st Emerald Groundhog Day Investment Forum
The investment team at Emerald believes that “Innovation Starts Small” – and are debuting a new whitepaper detailing the innovation-led investment opportunities in small-cap companies at their annual investment forum on February 1st. The 2024 Emerald Asset Management Groundhog Day Investment Forum is being held on Thursday, February 1st in suburban Philadelphia at The Valley Forge Sheraton – and online as an all-event virtual stream.
Jan 22, 2024 10:30 am ET
Investment Opportunities in the Innovation Economy Headline the 2024 Emerald Groundhog Day Investment Forum
Finding compelling innovation-led investment opportunities in U.S. small-cap stocks will be the theme of the 2024 Emerald Asset Management Groundhog Day Investment Forum, coming up on Thursday, February 1st at The Valley Forge Sheraton – and online as an all-event virtual stream. Emerald’s team of analysts and portfolio managers will focus on sector- and industry- specific opportunities as they introduce an exclusive new whitepaper on the Innovation Economy.
Jan 16, 2024 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Jan. 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 12, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 24,535 shares of its common stock and an aggregate of 15,817 restricted stock units to 16 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committ
Dec 18, 2023 03:05 pm ET
TransMedics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 18, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 8, 2024, at 3:00 p.m. Pacific Standard Time / 6:00 p.m. Eastern Standard Time.
Dec 12, 2023 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Dec. 12, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 7, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 9,547 shares of its common stock and an aggregate of 6,175 restricted stock units to 11 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee
Nov 14, 2023 03:05 pm ET
TransMedics to Present at the Piper Sandler 35th Annual Healthcare Conference
ANDOVER, Mass., Nov. 14, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York. The fireside chat will take place on Tuesday, November 28, 2023, at 2:30 p.m. Eastern Time.
Nov 07, 2023 08:31 am ET
Thinking about buying stock in Immix Biopharma, Vista Energy, Enphase Energy, TransMedics, or Medavail Holdings?
NEW YORK, Nov. 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMMX, VIST, ENPH, TMDX, and MDVL.
Nov 06, 2023 03:05 pm ET
TransMedics Reports Third Quarter 2023 Financial Results
ANDOVER, Mass., Nov. 6, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023.
Nov 03, 2023 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Nov. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 1, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 27,520 shares of its common stock and an aggregate of 17,670 restricted stock units to 10 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committe
Oct 23, 2023 04:05 pm ET
TransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023
ANDOVER, Mass., Oct. 23, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter 2023 after market close on Monday, November 6, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Oct 10, 2023 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Oct. 10, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 5, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 105,119 shares of its common stock and an aggregate of 67,288 restricted stock units to 21 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committ
Aug 01, 2023 11:00 am ET
TransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ Transplantation
Establishes the first national provider of air logistics dedicated to organ transplantation in the U.S.
Jul 26, 2023 05:09 pm ET
TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary
ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary.
Jul 26, 2023 04:05 pm ET
TransMedics to Present at the Canaccord Genuity 43rd Annual Growth Conference
ANDOVER, Mass., July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 43rd Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Wednesday, August 9, 2023, at 5:00 p.m. Eastern Standard Time.
Jul 20, 2023 04:05 pm ET
TransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023
ANDOVER, Mass., July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2023 after market close on Thursday, August 3, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Jun 06, 2023 10:55 am ET
Thinking about trading options or stock in Monday.Com, TransMedics, Builders FirstSource, Super Micro Computer, or Royal Caribbean Cruises?
NEW YORK, June 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MNDY, TMDX, BLDR, SMCI, and RCL.
May 30, 2023 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., May 30, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 24, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 87,472 shares of its common stock and an aggregate of 30,565 restricted stock units to 16 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of
May 16, 2023 11:45 am ET
Thinking about buying stock in Nu Holdings, Cabaletta Bio, CVRx, Alphatec Holdings, or TransMedics?
NEW YORK, May 16, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NU, CABA, CVRX, ATEC, and TMDX.
May 08, 2023 11:21 pm ET
TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028
ANDOVER, Mass., May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the upsize and pricing of $400 million aggregate principal amount of convertible senior unsecured notes that will mature on June 1, 2028, unless earlier redeemed, repurchased or converted. The offering was upsized from the previously announced offering size of $300 million aggregate principal amount of notes. TransMedics has also granted the ini
May 08, 2023 07:23 am ET
TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
ANDOVER, Mass., May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it intends to offer, subject to market and other conditions, $300 million aggregate principal amount of convertible senior unsecured notes that will mature on June 1, 2028, unless earlier redeemed, repurchased or converted. TransMedics also expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period be
May 01, 2023 04:05 pm ET
TransMedics Reports First Quarter 2023 Financial Results
ANDOVER, Mass., May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2023.
May 01, 2023 08:00 am ET
TransMedics Releases Inaugural Environmental, Social & Governance (ESG) Report
ANDOVER, Mass., May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that it has published its inaugural Environmental, Social & Governance (ESG) report.
Apr 17, 2023 04:05 pm ET
TransMedics to Report First Quarter 2023 Financial Results on May 1, 2023
ANDOVER, Mass., April 17, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2023 after market close on Monday, May 1, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Feb 24, 2023 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Feb. 24, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 20, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 72,774 shares of its common stock to seven employees and an aggregate of 17,092 restricted stock units to three employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants included stock opt
Feb 21, 2023 04:05 pm ET
TransMedics to Present at Upcoming March Investor Conferences
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two...
Feb 08, 2023 03:05 pm ET
TransMedics to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
ANDOVER, Mass., Feb. 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2022 after market close on Wednesday, February 22, 2023. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Feb 02, 2023 03:08 pm ET
TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations
ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately.
Dec 21, 2022 03:05 pm ET
TransMedics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, January 11, 2023, at 5:15 p.m. Pacific Standard Time / 8:15 p.m. Eastern Standard Time.
Nov 07, 2022 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Nov. 7, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 2, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 138,400 shares of its common stock to six employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee of the TransMedics Board of Directors and were gran
Nov 03, 2022 04:05 pm ET
TransMedics Reports Third Quarter 2022 Financial Results
Net revenue of $25.7 million, comprised of $24.3 million in sales revenue and $1.4 million favorable adjustment
Oct 20, 2022 04:05 pm ET
TransMedics to Report Third Quarter 2022 Financial Results on November 3, 2022
ANDOVER, Mass., Oct. 20, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter of 2022 after market close on Thursday, November 3, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Aug 29, 2022 04:05 pm ET
TransMedics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
ANDOVER, Mass., Aug. 29, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 20th Annual Global Healthcare Conference at the Sheraton New York. The fireside chat will take place on Monday, September 12, 2022, at 11:40 a.m. Eastern Time.
Aug 04, 2022 08:19 pm ET
TransMedics Announces Upsize and Pricing of Public Offering of Common Stock
ANDOVER, Mass., Aug. 4, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the upsize and pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares are being offered by TransMedics.
Aug 03, 2022 04:36 pm ET
TransMedics Announces Proposed Public Offering of Common Stock
ANDOVER, Mass., Aug. 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public offering of $100 million of its shares of common stock. All of the shares will be offered by TransMedics. TransMedics also expects to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount of up to 15% of the number of shares sold in the offering.
Aug 01, 2022 04:05 pm ET
TransMedics Reports Second Quarter 2022 Financial Results
Accelerated Commercial Momentum to Achieve Net Revenue of $20.5 million
Jul 26, 2022 04:05 pm ET
TransMedics to Present at the Canaccord Genuity 42nd Annual Growth Conference
ANDOVER, Mass., July 26, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Wednesday, August 10, 2022, at 8:00 a.m. Eastern Standard Time.
Jul 18, 2022 04:05 pm ET
TransMedics to Report Second Quarter 2022 Financial Results on August 1, 2022
ANDOVER, Mass., July 18, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Jun 03, 2022 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., June 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on June 1, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock to three employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee of the TransMedics Board of Directors and were granted
May 03, 2022 04:05 pm ET
TransMedics Reports First Quarter 2022 Financial Results
ANDOVER, Mass., May 3, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2022.
Apr 28, 2022 07:00 am ET
TransMedics Receives FDA PMA Approval of OCS™ DCD Heart Indication
ANDOVER, Mass., April 28, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS™ Heart System for use with organs from donors after circulatory death (DCD). The landmark approval stands to significantly expand the pool of eligible donor hearts in the United States and follows FDA PMA approval of the OCS™ Heart System for use
Apr 21, 2022 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., April 21, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on April 18, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 29,800 shares of its common stock to three employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee of the TransMedics Board of Directors and were gra
Apr 19, 2022 06:04 pm ET
TransMedics to Report First Quarter 2022 Financial Results on May 3, 2022
ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter of 2022 after market close on Tuesday, May 3, 2022. The TransMedics management team will host a corresponding conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT.
Apr 19, 2022 04:05 pm ET
TransMedics Announces the Presentation of New OCS™ Heart and OCS™ Lung Clinical Data at the International Society of Heart and Lung Transplantation 2022 Annual Meeting
ANDOVER, Mass., April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that new clinical data from its OCS™ Heart and OCS™ Lung clinical trials will be presented at the upcoming International Society of Heart and Lung Transplantation (ISHLT) 2022 Annual Meeting taking place April 27-30, 2022 in Boston, MA. The Company will also host a symposium and display its OCS™ technology at booth #419 at the conference.
Mar 01, 2022 03:05 pm ET
TransMedics to Present at the Oppenheimer's 32nd Annual Healthcare Conference
ANDOVER, Mass., March 1, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Oppenheimer 32nd Annual Healthcare Conference. Management is scheduled to present on Wednesday, March 16, 2022, at 3:20 p.m. Eastern Standard Time.
Feb 25, 2022 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Feb. 25, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on February 22, 2022, TransMedics granted non-qualified stock options to purchase an aggregate of 158,500 shares of its common stock to eight employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee of the TransMedics Board of Directors and were
Feb 23, 2022 03:05 pm ET
TransMedics Reports Fourth Quarter and Full Year 2021 Financial Results
ANDOVER, Mass., Feb. 23, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2021.
Feb 22, 2022 03:05 pm ET
TransMedics to Present at the Cowen 42nd Annual Healthcare Conference
ANDOVER, Mass., Feb. 22, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Cowen 42nd Annual Healthcare Conference. Management is scheduled to present on Wednesday, March 9, 2022, at 9:50 a.m. Eastern Standard Time.
Feb 09, 2022 03:05 pm ET
TransMedics to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
ANDOVER, Mass., Feb. 9, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23, 2022. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Jan 05, 2022 05:41 pm ET
TransMedics Announces Publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery
ANDOVER, Mass., Jan. 5, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the publication of OCS™ Liver PROTECT Trial Results in JAMA Surgery, a member of the Journal of the American Medical Association (JAMA) Network. The publication, titled Impact of Portable Normothermic Blood-Based Machine Perfusion on Outcomes of Liver Transplant, was published online on January 5, 2022. The OCS™ Liver System was approved by the
Dec 22, 2021 06:00 am ET
TransMedics to Present at the 40th Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 40th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 12, 2022, at 7:30 a.m. Eastern Standard Time.
Nov 11, 2021 03:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Nov. 11, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on November 5, 2021, TransMedics granted non-qualified stock options to purchase an aggregate of 240,500 shares of its common stock to eleven employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the Compensation Committee of the TransMedics Board of Directors and were
Nov 09, 2021 03:05 pm ET
TransMedics Reports Third Quarter 2021 Financial Results
ANDOVER, Mass., Nov. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2021.
Nov 04, 2021 04:05 pm ET
TransMedics to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum on Thursday, November 18, 2021.
Nov 04, 2021 07:00 am ET
TransMedics Announces Positive Top Line Results From the U.S. Randomized OCS DCD Heart Trial
ANDOVER, Mass., Nov. 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced positive topline results from its OCS donors after circulatory death (DCD) Heart Trial.
Oct 26, 2021 04:05 pm ET
TransMedics to Report Third Quarter 2021 Financial Results on November 9, 2021
ANDOVER, Mass., Oct. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter after market close on Tuesday, November 9, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Sep 29, 2021 07:00 am ET
TransMedics Receives FDA Approval for its OCS Liver System for Preservation and Assessment of Donor Livers for Transplantation
ANDOVER, Mass., Sept. 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS Liver System for use with organs from donors after brain death (DBD) and after circulatory death (DCD).
Sep 07, 2021 07:00 am ET
TransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplantation in the U.S.
ANDOVER, Mass., Sept. 7, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS Heart System for use with organs from donors after brain death (DBD).
Aug 26, 2021 04:05 pm ET
TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
ANDOVER, Mass., Aug. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a virtual fireside chat at the upcoming Morgan Stanley 19th Annual Global Healthcare Conference. The fireside chat will take place on Thursday, September 9, 2021 at 8:00 a.m. Eastern Time.
Aug 09, 2021 04:05 pm ET
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Aug. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on August 4, 2021, TransMedics granted non-qualified stock options to purchase an aggregate of 160,800 shares of its common stock to five employees as a material inducement for each employee's entry into employment with TransMedics. The options were approved by the TransMedics Board of Directors and were granted in accordance with Nasdaq L
Aug 05, 2021 04:05 pm ET
TransMedics Reports Second Quarter 2021 Financial Results
ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2021.
Jul 29, 2021 06:05 pm ET
TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs
ANDOVER, Mass., July 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its OCS™ Lung Solution for use in transplants using cold storage techniques. The solution, which is also cleared as a component of the company's OCS Lung System, is indicated for hypothermic flushing, storage and transportation of donor lungs for transplantation.
Jul 28, 2021 04:05 pm ET
TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference
ANDOVER, Mass., July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a virtual fireside chat at the upcoming Canaccord Genuity 41st Annual Growth Conference. The fireside chat will take place on Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time.
Jul 22, 2021 04:05 pm ET
TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021
ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Thursday, August 5, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Jul 14, 2021 09:00 pm ET
TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and discussion of TransMedics' clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Liver System.
Jul 14, 2021 07:05 am ET
TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System
ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that Nasdaq has halted trading of the company's common stock.
Jun 10, 2021 10:35 am ET
TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting
ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the U.S. Food and Drug Administration ("FDA") has announced the scheduling of a public advisory committee meeting during which it will review information regarding TransMedics' premarket approval application for the OCS Liver System. The Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee will meet on on Ju
Jun 08, 2021 04:05 pm ET
TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC
ANDOVER, Mass., June 8, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that the complete results of the OCS™ Liver PROTECT Trial ("PROTECT") were presented virtually at the American Transplant Congress on Tuesday June 8th, 2021. The presentation won the People's Choice Award for the most impactful presentation at the ATC 2021.
May 26, 2021 07:00 am ET
Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of Directors
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s...
Feb 16, 2021 03:05 pm ET
TransMedics to Present at the Cowen 41st Annual Healthcare Conference
ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming Cowen 41st Annual Healthcare Conference. Management is scheduled to present on Wednesday, March 3, 2021 at 3:20 p.m. Eastern Standard Time.
Feb 16, 2021 03:01 pm ET
TransMedics to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021
ANDOVER, Mass., Feb. 16, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the fourth quarter and full year 2020 after market close on Tuesday, March 2, 2021. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Dec 24, 2020 07:00 am ET
TransMedics to Present at the 39th Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass., Dec. 24, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that members of the management team will present virtually at the upcoming 39th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 13, 2020 at 5:20 p.m. Eastern Standard Time.
Dec 23, 2020 03:01 pm ET
TransMedics Appoints Merilee Raines to Board of Directors
ANDOVER, Mass., Dec. 23, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Merilee Raines to its Board of Directors and as a member of the Audit Committee, effective January 1, 2021. The Board appointed Ms. Raines as Chair of the Audit Committee, effective as of June 1, 2021.
Nov 04, 2020 03:01 pm ET
TransMedics Reports Third Quarter 2020 Financial Results
ANDOVER, Mass., Nov. 4, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended September 30, 2020.
Oct 29, 2020 04:02 pm ET
TransMedics to Participate in Upcoming Virtual Investor Conferences
ANDOVER, Mass., Oct. 29, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of the management team will be virtually participating in two upcoming investor conferences. TransMedics will participate in the Oppenheimer Fall MedTech Summit on November 12, 2020, followed by the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020.
Oct 21, 2020 04:01 pm ET
TransMedics to Report Third Quarter 2020 Financial Results on November 4, 2020
ANDOVER, Mass., Oct. 21, 2020 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the third quarter after market close on Wednesday, November 4, 2020. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
Sep 28, 2020 04:05 pm ET
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA has temporarily postponed the...
Sep 01, 2020 04:30 pm ET
TransMedics to Present at the 18th Annual Morgan Stanley Global Healthcare Conference
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be...
Aug 05, 2020 04:01 pm ET
TransMedics Reports Second Quarter 2020 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended...
Jul 28, 2020 04:01 pm ET
TransMedics to Present at the Canaccord 40th Annual Growth Conference
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today that members of management will be...
Jul 23, 2020 08:00 am ET
TransMedics to Report Second Quarter 2020 Financial Results on August 5, 2020
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for...
May 26, 2020 06:50 pm ET
TransMedics Announces Pricing of Public Offering of Common Stock
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the pricing of an underwritten public...
May 26, 2020 07:14 am ET
TransMedics Announces Proposed Public Offering of Common Stock
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the commencement of a proposed public...
May 26, 2020 07:09 am ET
TransMedics Announces Positive Top-line Results from U.S. Pivotal OCS™ Liver PROTECT Trial
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported positive top-line results from its U.S....
May 06, 2020 04:05 pm ET
TransMedics Reports First Quarter 2020 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended...
Apr 23, 2020 04:05 pm ET
TransMedics to Report First Quarter 2020 Financial Results on May 6, 2020
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for...
Apr 13, 2020 04:05 pm ET
TransMedics Provides COVID-19 Pandemic Update and Announces Preliminary Financial Results for First Quarter 2020
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced actions it is taking in response to the...
Mar 17, 2020 07:00 am ET
TransMedics Announces Temporary Postponement of OCS Heart FDA Advisory Panel Committee Meeting Due to COVID-19 Emergency
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the Company and FDA/CDRH have...
Mar 02, 2020 04:05 pm ET
TransMedics Reports Fourth Quarter and Full Year 2019 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter and year...
Feb 20, 2020 04:05 pm ET
TransMedics to Present at the Cowen 40th Annual Health Care Conference
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will be participating in the...
Feb 19, 2020 04:05 pm ET
TransMedics to Report Fourth Quarter and Full Year 2019 Financial Results on March 2, 2020
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for...
Dec 19, 2019 08:00 am ET
TransMedics to Present at the 38th Annual J.P. Morgan Healthcare Conference
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will present at the upcoming...
Dec 04, 2019 08:00 am ET
TransMedics’ Organ Care System (OCS™) Technology Used in First U.S. Adult Human Heart Transplants From DCD Donors
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the completion of the first successful...
Nov 06, 2019 07:30 am ET
TransMedics Reports Third Quarter 2019 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended...
Oct 23, 2019 04:05 pm ET
TransMedics Announces Change to Time of Third Quarter 2019 Earnings Conference Call on Wednesday, November 6
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will now release financial results...
Oct 16, 2019 04:05 pm ET
TransMedics to Report Third Quarter 2019 Financial Results on November 6, 2019
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for...
Aug 26, 2019 04:05 pm ET
TransMedics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will be participating in the...
Aug 07, 2019 04:05 pm ET
TransMedics Reports Second Quarter 2019 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended...
Jul 30, 2019 08:30 am ET
TransMedics Announces Successful Long Distance Retrieval and Transplantation of Donor Lungs from Hawaii Using Organ Care System (OCS™)
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the OCS Lung technology was used in two...
Jul 25, 2019 04:05 pm ET
TransMedics to Present at the 39th Annual Canaccord Genuity Global Growth Conference
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the company will be participating in the...
Jul 17, 2019 04:05 pm ET
TransMedics to Report Second Quarter 2019 Financial Results on August 7, 2019
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for...
Jun 11, 2019 04:05 pm ET
TransMedics Reports First Quarter 2019 Financial Results
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today reported financial results for the quarter ended...
Jun 03, 2019 08:00 am ET
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations o
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it has received an FDA PMA approval...
May 30, 2019 04:05 pm ET
TransMedics to Report First Quarter 2019 Financial Results on June 11, 2019
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for...
May 06, 2019 04:15 pm ET
TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced the closing of its initial public offering...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.